Antibody and Drug Discovery Market Size, Share, Growth, Trends, and Global Industry Analysis: By Method (Phage Display, Hybridoma & Others), By Antibody Type (Humanized Antibody, Human Antibody, Chimeric Antibody, Murine Antibody), By Type (Monoclonal, Polyclonal, Bispecific, Intracellular), By End users (Pharmaceutical and Biotechnology industry, Research laboratory, Academic laboratory), and Region

Antibody and drug discovery market size was valued at US$ 6,343.8 million in 2023 and is poised to grow at 11.6% CAGR from 2024 to 2030. Antibody-based medications may target substances which is linked to disease, this allows for the development of highly targeted and effective medicines. As a result, pharmaceutical companies and research institutes are investing greater funds in the development of antibody therapeutics in an effort to fill medical gaps and provide patients with more individualised treatment options. The main key drivers of market are as the prevalence of infectious and chronic diseases is on the rise and people are becoming more conscious of early  detection and personalised medicine.

Moreover, the market also has grown as a result of increased need for more effective, efficient, and affordable therapies for a range of diseases as well as increased R&D spending on antibody development. However, the restraining factors of the market are economic considerations that impact the antibody and drug discovery , such as a drug's cost-effectiveness and potential of success, also impact antibody research. Pharmaceutical companies are attracted by the opportunity of the market by producing beneficial medical antibodies that are in high demand, despite the huge initial expenditures associated with research and development. The development of antibody therapy to stop future infectious diseases is receiving increased funding and attention as a result of this experience, the market trends are emerging as increasing investment in the platform and service domain for antibody drug discovery.

Additionally due to the growing number of applications for antibody drug discovery platforms and services, investors have become increasingly interested in the business, which has led to a major rise in investment activity in this market. For isnatnce, In January 2023, IASO Biotherapeutics raised US$ 75 million in a venture series C round for development of novel cell therapies and biologics for oncology and autoimmune diseases.

Key Developments

• In September 2022, Abzena, a top supplier of biologics and antibody drug conjugates, said that it will expand its R&D capacity in Cambridge to facilitate the advancement of swift antibody discovery.
• In June 2023, Sanyou Biopharmaceuticals a Chinese-based business, introduced its Sanyou Super Trillion Common Light Chain Antibody Discovery Platform. This platform aids in the identification of bispecific antibody forms.